SPEVATAMIG
UNII LVB74L4PM2

Substance Identification & Data

This profile provides standardized clinical and technical data for Spevatamig, uniquely identified by the FDA Unique Ingredient Identifier (UNII) LVB74L4PM2.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2928515-36-8 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

LVB74L4PM2

CAS Registry Number

2928515-36-8

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

SPEVATAMIG

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C190118

National Cancer Institute reference terminology for clinical and research data.

INN ID

13260

Sequential identifier assigned via the WHO International Nonproprietary Name program.

USAN ID

NO-162

Identifier assigned by the United States Adopted Names Council.

Substance Type

Spevatamig

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Spevatamig. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

Spevatamig

Common Names & Synonyms

H-gamma1 heavy chain anti-CD47 (1-444), G1v92-1 VH E44, CH1 E77 [VH E44 (Homo sapiens IGHV1-46*01 (87.6%) Q44>E (39') -(IGHD) -IGHJ4*01 (100%), CDR-IMGT [8.8.7] (26-33.51-58.97-103)) (1-114) -Homo sapiens IGHG1*01, G1m17,1 CH1 K120, CH3 D12, L14, CH1 E77, G1v93 CH1 C12, G1v37 h S5, G1v74 CH3 C10, G1v32 CH3 W22 (knob) (CH1 K12>C (130), G77>E (163), K120 (211) (115-212), hinge 1-15 C5>S (217) (213-227), CH2 (228-337), CH3 S10>C (351), D12 (353), L14 (355), T22>W (363) (338-442), CHS (443-444)) (115-444)], (130-209')- disulfide with L-kappa light chain anti-CD47 (1'-214') Kv92-1 V-KAPPA K44, C-KAPPA K3 [V-KAPPA K44 (Homo sapiens IGKV3-20*01 (83.3%) Q44>K (38') -IGKJ1*01 (91.7%), CDR-IMGT [6.3.9] (27'-32'.50'-52'.89'-97')) (1'-107') -Homo sapiens IGKC*01 (98.1%) Km3 A45.1, V101, K3, KCv37 C121, S126 (C-KAPPA S3>K (114'), A45.1 (153'), V101 (191'), F121>C (209'), C126>S (214')) (108'-214')]; H-gamma1 heavy chain anti-CLDN18 (1-449), G1v92-2 VH K44, CH1 K77 [VH K44 (Homo sapiens IGHV3-48*01 (87.8%) Q44>K (39'') -(IGHD) -IGHJ4*01 (92.9%), CDR-IMGT [8.8.12] (26''-33''.51''-58''.97''-108'')) (1''-119'') -Homo sapiens IGHG1*01, G1m17,1 CH1 K120, CH3 D12, L14, CH1 K77, G1v75 CH3 C5, G1v33 CH3 S22, A24, V86 (hole) (CH1 G77>K (168''), K120 (216'') (120''-217''), hinge 1-15 (218''-232''), CH2 (233''-342''), CH3 Y5>C (351''), D12 (358''), L14 (360''), T22>S (368''), L24>A (370''), Y86>V (409'') (343''-447''), CHS (448''-449'')) (120''-449'')], (222''-220''')-disulfide with L-kappa light chain anti-CLDN18 (1'''-220''') Kv92-2 V-KAPPA E44, C-KAPPA E3 [V-KAPPA E44 (Musmus/Homsap (Mus musculus IGKV8-19*01 (79.2%) Q44>E (44''') -IGKJ2*03 (81.8%) S120>Q (106'''), L124>V (110''')/Homo sapiens IGKV1-39*01 (78.2%) Q44>E (44''') -IGKJ1*01 (100%), CDR -IMGT [12.3.9] (27'''-38'''.56'''-58'''.95'''-103''')) (1'''-113''') -Homo sapiens IGKC*01 (99.1%) Km3 A45.1, V101, E3 (C-KAPPA S3>E (120'''), A45.1 (159'''), V101 (197''')) (114'''-220''')]; dimer (223-228'':226-231'':351-351'')-trisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa

Immunoglobulin G1 [168-lysine,351-cysteine,368-serine,370-alanine,409-valine], anti-(human claudin CLDN18.2) (human-Mus musculus monoclonal PT886 γ1-chain), disulfide with [120-glutamic acid] human-Mus musculus monoclonal PT886 κ-chain, (228→223′),(231→226′),(351→351′)-tris(disulfide) with immunoglobulin G1 [130-cysteine,163-glutamic acid,217-serine,351-cysteine,363-tryptophan] anti-(human CD47 antigen) (human-Mus musculus monoclonal PT886 γ1-chain) disulfide with [114-lysine,209-cysteine,214-serine] human-Mus musculus monoclonal PT886 κ-chain

SPEVATAMIG [USAN]

Spevatamig [WHO-DD]

immunoglobulin (H-gamma1_L-kappa)_(H-gamma1_L-kappa), anti-[Homo sapiens CD47 (CD47 molecule, integrin associated protein, IAP, MER6, OA3) and anti-[Homo sapiens CLDN18 (claudin 18, claudin-18, SFTPJ, surfactant associated protein J) isoform 2], bispecific

spevatamig [INN]